Clinical trial registry record

Systemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation

A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Not Yet Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 20, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06887075
Last registry update
March 20, 2025
Status
Not Yet Recruiting
Phase
Phase not reported
Sponsor
University Hospital, Bordeaux
Enrollment
60
Countries
France
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
NON RANDOMIZED · PARALLEL · DIAGNOSTIC · NONE
Evidence population
Human clinical study registration
Participants
60
Population
ALL · 70 Years
Duration
2025-04-15 to 2027-02-15
Intervention
Blood sample; Geriatric assessment standardized
Comparator
Frail Patients; non frail patients
Outcomes measured
IL1 — at recruitment (up to 30 days); IL18 — at recruitment (up to 30 days); inflammasomes genes — at recruitment (up to 30 days); inflammasome platform — at recruitment (up to 30 days); Weight — at enrollment (Day 0), at recruitment (up to 30 days); Activity — at enrollment (Day 0), at recruitment (up to 30 days); Gait — at enrollment (day 0), at recruitment (up to 30 days); Handgrip strength — at enrollment (day 0), at recruitment (up to 30 days); Comorbidity — at recruitment (up to 30 days); decline — at recruitment (up to 30 days); Physical performance — at recruitment (up to 30 days); Cognitive functions — at recruitment (up to 30 days); Depression — at recruitment (up to 30 days); Nutrition — at recruitment (up to 30 days); Snellen test — at recruitment (up to 30 days); ADL — at recruitment (up to 30 days); Immunophenotyping — at recruitment (up to 30 days); CRP — at recruitment (up to 30 days); IL-6 — at recruitment (up to 30 days); MCP-1 — at recruitment (up to 30 days)
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Frailty · 100%Title contains controlled term: frailty. Abstract contains controlled term: frailty. Source terminology contains: frailty. Title supplies longevity context: frailty, frail. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.